New CD22 CAR-T cell therapy gives hope for acute lymphoblastic leukemia
A new clinical study has shown that CD22 CAR-T cell therapy is a highly effective and safe treatment option for children with B acute lymphoblastic leukemia.
A new clinical study has shown that CD22 CAR-T cell therapy is a highly effective and safe treatment option for children with B acute lymphoblastic leukemia.
B acute lymphoblastic leukemia (B-ALL) is the most common type of cancer in children. It affects certain cells in the immune system called B cells. B-ALL is usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or relapsed (r/r) B-ALL patients. However, some patients would become refractory to all these treatment options and relapse.
New emerging CAR-T immunotherapy is a type of treatment in which a patient’s T cells are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR).
A study presented at the 23rd Congress of European Hematology Association by Dr Jing Pan, who is affiliated with the Beijing Boren Hospital in China evaluated humanized CD22-CAR-T cell therapy as a treatment option for pediatric r/r B-ALL patients who failed multiple lines of treatment including allo-HCT and CD19-CAR-T cell therapy. Researchers found in this study that CD22-CAR-T cell therapy is highly effective with an overall response rate (ORR) of 86.7% and complete remission (CR) rate of 80.0%. The response cases achieved progression-free survival (PFS) rate of 91.7% during a median follow-up of 108 (46-199) days. It also has excellent safety profile with minor side effects and no death.
The data from this study suggests that CD22-CAR-T cell therapy is a highly effective and safe treatment option for pediatric r/r B-ALL patients even after they failed CD19-CAR-T therapy and allo-HCT.
Reference:https://medicalherald.com/new-cd22-car-t-cell-therapy-gives-hope-for-acute-lymphoblastic-leukemia/
ارسال به دوستان